Open AccessP409: NPM1 MUTATED SAMPLES ARE ESPECIALLY VULNERABLE WHEN TARGETING RAC1 IN PATIENT‐DERIVED AML CELLS IN VITRO
Author(s) -
Hemsing A.,
Rye K. P.,
Hatfield K. J.,
Reikvam H.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000844524.09487.4d
Subject(s) - rac1 , myeloid leukemia , leukemia , apoptosis , cancer research , gemtuzumab ozogamicin , propidium iodide , microbiology and biotechnology , in vitro , flow cytometry , biology , chemistry , immunology , programmed cell death , cd34 , cd33 , signal transduction , biochemistry , stem cell